Ginkgo biloba Damo injection combined with troxerutin regulates the TLR4/NF-κB pathway and promotes the recovery of patients with acute cerebral infarction.

Objective: Analysis of the effect of Ginkgo biloba Damo injection combined with troxerutin on patients with acute cerebral infarction (ACI) by regulating the TLR4/NF-κB signaling pathway.

Methods: 150 patients with ACI were recruited for a prospective study. These patients were randomly divided into Ginkgo biloba Damo treatment group (n=75) and combined treatment group (Ginkgo biloba Damo + troxerutin, n=75) bilobabiloba. The patients in both groups were treated with conventional treatment. In addition, patients in the Ginkgo biloba Damo treatment group were treated with Ginkgo biloba Damo injection, and those in the combined treatment group were treated with Ginkgo biloba Damo injection combined with troxerutin. The National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) of the two groups were compared. The serum levels of GSH-Px, OX-LDL, CAT, TLR4, NF-κB p65, TNF-α, IL-1β and IL-6 were detected. The therapeutic effects of the two groups were compared.

Results: After treatment, compared with the Ginkgo biloba Damo group, the combined treatment group had a lower NIHSS score and lower expression levels of OX-LDL, TLR4, NF-κB p65, TNF-α, IL-1β, and IL-6, but higher Barthel score and total effective rate as well as higher serum levels of GSH-Px and CAT (all P<0.05).

Conclusion: Ginkgo biloba Damo injection combined with troxerutin can improve the neurologic function and activities of daily life in patients with ACI, which can also regulate the TLR4/NF-κB signaling pathway and downstream inflammatory factors to reduce brain tissue inflammation and oxidative stress damage.